Data from: Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Cite this dataset
Roy, Bhaskar et al. (2019). Data from: Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors [Dataset]. Dryad. https://doi.org/10.5061/dryad.3ng4b2g
Objective: To explore the association of peripheral neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) use in cancer patients. Methods: Published data search up to November 2018 reporting peripheral neuropathy in cancer patients treated with VEGFR-TKIs was performed. The primary outcome was presence of peripheral neuropathy at the end of the trial. Random-effects meta-analysis was performed to estimate Relative Risk (RR) of individual treatment. Results: Thirty Randomized Clinical Trials (RCTs) including 12,490 cancer patients were included in this analysis. Eight studies compared VEGFR-TKIs with placebo and the remaining studies compared VEGFR-TKIs with the standard chemotherapeutic regimen. When compared against placebo VEGFR-TKIs were associated with a higher risk of peripheral neuropathy (RR=1.76, 95% CI 1.13-2.75, p-value 0.01). Similarly, a stronger association was noted for sensory neuropathy with VEGFR-TKIs monotherapy (RR = 1.61; 95% CI 1.09-2.37, p = 0.02). Risk of peripheral neuropathy with VEGFR-TKIs was higher even when they were compared against control (either placebo or standard chemotherapeutic agents); RR=1.08, 95% CI 1.01-1.15, p-value 0.03. High-grade neuropathy (RR 1.28, 95% CI 1.06-1.54, p-value <0.01) and high-grade sensory neuropathy (RR 1.38, 95% CI 1.09-1.74, p-value <0.01) were noted more frequently with VEGFR-TKIs treatment compared against control. Conclusions: VEGFR-TKIs therapy appeared to be associated with an increased risk of neuropathy.